Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Intangibles (2017 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Intangibles for 9 consecutive years, with $6.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Intangibles changed 0.0% year-over-year to $6.7 million, compared with a TTM value of $6.7 million through Sep 2025, changed 0.0%, and an annual FY2024 reading of $6.7 million, down 24.13% over the prior year.
  • Intangibles was $6.7 million for Q3 2025 at Kiora Pharmaceuticals, roughly flat from $6.7 million in the prior quarter.
  • Across five years, Intangibles topped out at $10.8 million in Q4 2021 and bottomed at $6.7 million in Q3 2024.
  • Average Intangibles over 5 years is $9.0 million, with a median of $9.5 million recorded in 2021.
  • The sharpest move saw Intangibles skyrocketed 148.55% in 2021, then dropped 24.13% in 2024.
  • Year by year, Intangibles stood at $10.8 million in 2021, then fell by 0.17% to $10.7 million in 2022, then dropped by 18.01% to $8.8 million in 2023, then dropped by 24.13% to $6.7 million in 2024, then changed by 0.0% to $6.7 million in 2025.
  • Business Quant data shows Intangibles for KPRX at $6.7 million in Q3 2025, $6.7 million in Q2 2025, and $6.7 million in Q1 2025.